TyG Index Test

Your fasting blood sugar can look perfectly normal for a decade while insulin resistance quietly damages your blood vessels, liver, and kidneys. The TyG Index (triglyceride-glucose index) catches that hidden dysfunction by combining two routine lab values, fasting triglycerides and fasting glucose, into a single number that reflects how efficiently your cells are responding to insulin. It picks up metabolic trouble that a standard glucose reading alone will miss.

The formula is straightforward: TyG = ln(fasting triglycerides in mg/dL x fasting glucose in mg/dL / 2). The natural logarithm compresses a wide range of values into a tidy scale, typically landing between about 7.5 and 10 in most adults. When validated head-to-head against the gold standard for measuring insulin resistance (a labor-intensive hospital procedure called the euglycemic-hyperinsulinemic clamp), the TyG Index showed 96.5% sensitivity and 85.0% specificity. That means it catches nearly all cases of true insulin resistance and rarely flags someone who does not have it.

Why This Number Matters More Than Fasting Glucose Alone

Fasting glucose tells you what your blood sugar is doing right now. But insulin resistance is a process, not a snapshot. Your body can keep blood sugar normal for years by pumping out more and more insulin to compensate. By the time glucose finally rises above the normal range, the underlying metabolic damage has been accumulating for a long time. The TyG Index picks up the signal earlier because triglycerides tend to climb as insulin resistance develops, often well before glucose budges.

In a large study of people with completely normal fasting glucose, the TyG Index still identified those at higher risk for future diabetes and cardiovascular disease. It outperformed the more commonly used HOMA-IR (a calculation that requires an insulin blood test) for predicting metabolic syndrome, with an area under the curve of 0.827 compared to 0.784. And it requires no additional lab work beyond what a standard metabolic panel already provides.

Type 2 Diabetes Risk

The link between an elevated TyG Index and future diabetes is one of the strongest in the metabolic literature. A meta-analysis pooling over 270,000 people found that those in the highest TyG category were about 3.5 times as likely to develop type 2 diabetes as those in the lowest category (adjusted relative risk 3.54), and this held up after accounting for age, drinking habits, and HDL cholesterol. The risk curve is not linear: it steepens sharply once the TyG Index climbs above roughly 8.6.

In a Korean cohort of over 5,300 non-diabetic adults followed for about five years, people in the top quartile of TyG had about 4 times the risk of developing diabetes compared to those in the bottom quartile, even after adjusting for BMI, waist circumference, blood pressure, family history, and insulin levels. A TyG cutoff of 8.8 predicted new diabetes regardless of whether the person was lean or overweight.

Heart Disease and Stroke

Insulin resistance does not just affect blood sugar. It drives inflammation, endothelial dysfunction (damage to the inner lining of blood vessels), and the buildup of arterial plaque. The TyG Index captures this cardiovascular dimension. A meta-analysis of over 6.3 million participants found that those with the highest TyG levels were about twice as likely to develop coronary artery disease (hazard ratio 2.01) and about 1.5 times as likely to experience a composite cardiovascular event compared to those with the lowest levels.

For stroke specifically, the picture is clearer for blockages than for bleeds. A meta-analysis of eight cohort studies with nearly 5.8 million participants found that the highest TyG category carried a 26% higher risk of stroke overall (hazard ratio 1.26), with the association driven primarily by ischemic stroke (the type caused by a clot) rather than hemorrhagic stroke (the type caused by a bleed). A separate pooled analysis found no significant association with hemorrhagic stroke. A Greek validation study found that a TyG cutoff of 8.46 meaningfully improved cardiovascular risk prediction beyond the standard European risk calculator.

Kidney Function

Your kidneys are among the first organs to show damage from insulin resistance, often long before you notice any symptoms. A meta-analysis of 86,038 participants across 11 studies found that people in the highest TyG category had a 52% higher risk of developing chronic kidney disease (adjusted relative risk 1.52), with zero statistical disagreement between studies.

A Japanese study of over 10,700 people with initially healthy kidneys found that a TyG of 8.76 or higher more than doubled the risk of losing at least 25% of kidney function over about three years (hazard ratio 2.25). This association held across every subgroup the researchers tested, including different ages, sexes, BMI ranges, and baseline kidney function levels. Reduced kidney function also appears to amplify the cardiovascular risk associated with a high TyG, creating a feedback loop: kidney damage worsens metabolic dysfunction, which worsens kidney damage.

Fatty Liver Disease

Metabolic dysfunction-associated fatty liver disease (formerly called nonalcoholic fatty liver disease, or NAFLD) is tightly linked to insulin resistance, and the TyG Index is one of the simpler ways to screen for it. A meta-analysis of nearly 122,000 people found that elevated TyG levels predicted fatty liver disease with an area under the curve of 0.705. People with a high TyG had about 2.4 times the odds of having fatty liver compared to those with a low TyG.

Trajectory matters here too. A large population study that tracked TyG over time found that people whose TyG was rising had 2.19 times the risk of developing fatty liver compared to those whose values stayed consistently low. This makes the TyG Index especially useful for monitoring liver metabolic health over serial blood draws.

Mortality

The evidence on whether TyG predicts death is more nuanced than for disease incidence. A large Italian study of over 16,600 adults followed for 12 years found that TyG predicted both all-cause and cardiovascular mortality after adjustment for standard risk factors. (That study used a slightly different version of the formula that produces values roughly half the standard TyG scale, so its cutoffs of 4.62 and 4.53 correspond approximately to 9.2 and 9.1 on the standard scale used in most other research.) But a meta-analysis across multiple populations found no statistically significant link between TyG and either cardiovascular mortality (hazard ratio 1.10) or all-cause mortality (hazard ratio 1.08). The signal may be strongest in younger adults: a U.S. study of over 20,000 adults found the association with mortality was significant in people under 65 but attenuated in older age groups.

Reference Ranges

No major medical society has formally adopted universal TyG Index cutoffs, and published thresholds vary by population, sex, ethnicity, and the outcome being predicted. The ranges below draw from the largest validation studies and offer a practical framework for interpretation. Because the TyG Index is calculated (not directly measured by a lab instrument), there is no assay variation to worry about, but the individual triglyceride and glucose readings that feed the formula can shift with fasting status, illness, and medications.

These tiers are drawn from published research across U.S., European, and Asian populations. Some studies have found that women may not reach equivalent diabetes risk until a TyG of 9.0 or higher, while men show risk escalation starting at 8.0. Ethnic variation is real: optimal cutoffs for coronary heart disease risk ranged from 8.51 in a British cohort to 9.72 in a Chinese cohort. Compare your results within the same context over time rather than treating any single threshold as absolute.

Tracking Your Trend

A single TyG reading is a useful starting point, but the real power of this marker comes from watching it over time. Your TyG can shift with diet, exercise, weight changes, and medications, and those shifts carry independent prognostic weight. A study following participants for more than a decade found that people whose TyG fluctuated substantially between visits had a higher risk of diabetes (hazard ratio 1.18 for the most variable group), cardiovascular disease, and even death, compared to those whose values stayed stable. The average TyG across multiple visits was a better predictor of all major health outcomes than any single baseline measurement.

Another large cohort found that both rising and falling TyG trajectories over time predicted higher cardiometabolic risk compared to stable levels, reinforcing the value of consistency. For practical purposes, get a baseline TyG, retest in 3 to 6 months if you are making diet or exercise changes to see whether the number is moving in the right direction, and then check at least annually. If your TyG is elevated, more frequent monitoring (every 3 to 4 months) helps you gauge whether your intervention is working before you wait a full year.

When Results Can Be Misleading

Because the TyG Index is built from two lab values, anything that transiently spikes your triglycerides or glucose can produce a misleadingly high result. Acute illness and physiological stress are the biggest offenders. Infections, surgery, or significant physical trauma trigger stress hormones that simultaneously raise blood sugar and mobilize fat, potentially pushing TyG well above your true baseline. Wait at least two to three weeks after recovering from an acute illness before drawing blood for TyG interpretation.

Fasting status matters. While one study found that postprandial triglycerides rise by only about 26 mg/dL on average four hours after a meal (a modest shift), the TyG Index was validated using fasting samples, and non-fasting draws introduce unnecessary variability. Fast for at least 8 to 12 hours before your blood draw.

Several medications shift TyG without reflecting a change in your underlying metabolic health. Corticosteroids (such as prednisone and dexamethasone) increase both glucose and triglycerides through stress-hormone pathways, and can meaningfully elevate your TyG while you are on them. Statins present a paradox: they lower triglycerides but can modestly increase glucose, with the net effect on TyG depending on dose and baseline levels. If you are taking any of these medications, mention them when interpreting your result, and consider tracking your TyG both on and off therapy to understand your true baseline.

Proton pump inhibitors (PPIs) have shown inconsistent effects on glucose and insulin resistance across studies, so their impact on TyG is likely small but not zero. Thyroid medications (levothyroxine) lower triglycerides in people with underactive thyroid, which can improve TyG as part of the intended treatment effect rather than as an artifact.